BRAF Recombinant Monoclonal Antibody

Code CSB-RA171021A0HU
Size US$210
Order now
  • IHC image of CSB-RA171021A0HU diluted at 1:100 and staining in paraffin-embedded human prostate cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
  • IHC image of CSB-RA171021A0HU diluted at 1:100 and staining in paraffin-embedded human testis tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
Serine/threonine-protein kinase B-raf (EC (Proto-oncogene B-Raf) (p94) (v-Raf murine sarcoma viral oncogene homolog B1), BRAF, BRAF1 RAFB1
Species Reactivity
A synthesized peptide derived from human B Raf
Immunogen Species
Homo sapiens (Human)
Rabbit IgG
Clone No.
Purification Method
It differs from different batches. Please contact us to confirm it.
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Tested Applications
Recommended Dilution
Application Recommended Dilution
IHC 1:50-1:200
Troubleshooting and FAQs
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

B lymphocytes were obtained from an animal immunized with a synthesized peptide derived from human BRAF. These cells were then fused with myeloma cells to generate hybridomas, whose variable light (VL) and variable heavy (VH) domains were sequenced to create a vector for recombinant generation. The resulting vector was transfected into cells for culture and production of the BRAF recombinant monoclonal antibody. The antibody was purified using affinity chromatography, and its specificity for human BRAF was verified using ELISA and IHC applications.

The BRAF protein is a member of the Raf family of serine/threonine kinases and plays an important role in the regulation of cell growth and proliferation. When activated, BRAF can phosphorylate and activate the downstream effector MEK1/2, which in turn activates the MAPK/ERK signaling pathway. This pathway is involved in many cellular processes, including cell proliferation, differentiation, survival, and apoptosis. Mutations in BRAF are commonly found in a variety of cancers, including melanoma, colorectal cancer, and thyroid cancer.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway. May play a role in the postsynaptic responses of hippocampal neurons.
Gene References into Functions
  1. Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues. PMID: 29879227
  2. On adjusted analysis specifically of the chemotherapy effect in each subgroup, only patients in the presumed Lynch (HR 0.260, 95% CI, 0.09-0.80, P < 0.01) and other BRAF groups (HR 0.45, 95% CI, 0.23-0.87, P < 0.01) had a significant survival benefit from chemotherapy. PMID: 30399198
  3. BRAF V600E is associated with distinct histomorphologic features in nevi. These features may contribute to improving the accuracy of classification and diagnosis of melanocytic neoplasms. PMID: 29653212
  4. Studies have demonstrated that suspicious US features are associated with the BRAFV600E mutation, as well as malignancy in atypia of undetermined significance/follicular lesion of undetermined significance nodules. PMID: 28877096
  5. It was found that RTK inactivation may help to overcome resistance to B-RAF inhibitors via inhibition of tyrosine kinase phosphorylation and a subsequent blocking of the PI3K-AKT-mTOR and MEK-ERK1/2 downstream signaling pathways. The changes eventually mitigated the cell growth and enhanced the Vemurafenib-dependent cell cycle arrest. PMID: 29989578
  6. The pan-RAF inhibitor sorafenib is not affected by expression of BRAF deletion variant. PMID: 29605720
  7. suggests the significance of the BRAFV600E mutation and activation of Wnt signaling pathway in the carcinoma cells PMID: 30223266
  8. Expression of BRAF V600E, RET/PTC, and concomitant expression of BRAF V600E and RET/PTC were significantly associated with patient age and lymph node metastasis (P<0.05).Of the 50 patients with Papillary Thyroid Carcinoma, 37 patients expressed the BRAF V600E gene mutation, eight patients expressed RET/PTC, and five patients showed concomitant BRAF V600E and RET/PTC. PMID: 30254191
  9. This study shows the correlation of blood BRAF(V600E) levels in response to treatment in patients with BRAF(V600E)-positive tumors with all stages of disease. PMID: 29378474
  10. BANCR is downregulated in ccRCC tissues and cell lines, and is associated with ccRCC progression. Thus, BANCR may represent a novel prognostic biomarker and a potential therapeutic target for ccRCC patients PMID: 30200918
  11. Study reports a S6K/PP1alpha/B-Raf pathway that activates MAPK signaling in PI3K/AKT-driven cancers and is opposed by the promyelocytic leukemia (PML) tumor suppressor. Its importance in regulating prostate cancer cell migration and invasion and in metastatic human prostate cancer is demonstrated. PMID: 29335436
  12. novel rearrangement of BRAF present in both infantile fibrosarcoma and cellular congenital mesoblastic nephroma PMID: 29915264
  13. differentially expressed Long Noncoding RNAs correlated with BRAF(V600E) in Papillary Thyroid Cancer. PMID: 28490781
  14. The data are consistent with independent RNAseq data from serial biopsies of melanoma patients treated with BRAF inhibitors. PMID: 29558679
  15. trichostatin A does not alter HDAC transcripts nor BRAF itself, but down-regulates critical components of the MAPK/MEK/BRAF oncogenic pathway, initiating a mitotic arrest. PMID: 30194076
  16. BRAF V600E mutation is associated with increased risk of skin metastases in chemo-resistant metastatic colorectal cancer. PMID: 29380640
  17. BRAF(V600E) gain-of-function mutation has been reported in over 50% of Erdheim-Chester disease patients. PMID: 29556768
  18. Presence of BRAFV600E mutations in melanoma is detecting by immunochemistry using clone VE1. PMID: 29221650
  19. results confirm that BRAF V600E-positive hairy cell leukemia is a relatively rare disorder in the Japanese leukemia patient population. PMID: 30043333
  20. BRAF and EGFR inhibitors are able to synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells PMID: 29534162
  21. A diligent morphological examination to look for the presence of hairy cells along with flow cytometric immunophenotyping showing consistent bright expression of CD200, in addition to well-described characteristic immunophenotype, helps in correctly diagnosing the case. This can be further confirmed by the consistent presence of V600E point mutation in BRAF gene. PMID: 30197362
  22. BRAF mutations are associated with colorectal liver metastases. PMID: 29937183
  23. Multivariate analyses revealed that the PIK3CA mutation and clinical T stage were independent favorable prognostic factors (hazard ratio 0.34, 95% confidence interval: 0.12-0.96, p = 0.042). PIK3CA mutations were significantly associated with APC alterations (p = 0.0007) and BRAF mutations (p = 0.0090). PMID: 30115035
  24. The present findings suggested that miR9 may suppress the viability ofpapillary thyroid carcinoma (PTC) cells and inhibit tumor growth through directly targeting the expression of BRAF in PTC. PMID: 29767243
  25. MET inactivation in the context of the BRAF-activating mutation is driven through a negative feedback loop involving inactivation of PP2A phosphatase, which in turn leads to phosphorylation on MET inhibitory Ser985. PMID: 30224486
  26. Data show that glycogen synthase kinase 3 (GSK3) and proto-oncogene proteins B-raf (BRAF)/MAPK signaling converges to control microphthalmia-associated transcription factor MITF (MITF) nuclear export. PMID: 30150413
  27. these results indicated that STAT3-mediated downexpression of miR-579-3p caused resistance to vemurafenib. Our findings suggest novel approaches to overcome resistance to vemurafenib by combining vemurafenib with STAT3 sliencing or miR-579-3p overexpression. PMID: 30010109
  28. Despite the presence of histological findings indicating long-standing gastroesophageal reflux in 25%, as well as symptomatic gastroesophageal reflux in more than 40%, there was no detectable tissue expression of KRAS or BRAF mutations in adult patients treated for esophageal atresia in childhood. PMID: 28873491
  29. A report of BRAF mutations in acute myeloid leukemias (AML) found mutations only in de novo AML with monocytic differentiation. PMID: 27545333
  30. The occurrence of BRAF V600E mutations in ganglioglioma is common, and their detection may be valuable for the diagnosis and treatment in ganglioglioma. PMID: 30220118
  31. Following adjustment for sex, logistic regression analysis showed that BRAFV600E mutation, transforming growth factor beta (TGF-beta) expression, age, and tumor size are risk factors that can affect tumor clinical stage (p < 0.05). Based on the results of this analysis, we generated a matrix that incorporated 4 variables: patient age, tumor size, BRAFV600E mutation, and TGF-beta expression. PMID: 28892804
  32. Studied frequency of BRAF 1799T>A mutation in Mexican Papillary Thyroid Cancer patients. PMID: 29808165
  33. The frequency of BRAF mutations was significantly higher in Serrated Lesions subgroups with highly methylated epigenotype tumors and microsatellite instability. PMID: 29974407
  34. The rate of EGFR mutation was significantly higher in female and non-smoker patients. In TTF-1 positive cases EGFR mutation was more frequent. Age of the patients over 62-year old was correlated with KRAS mutations. The concordance between ALK IHC and FISH was 58.3%. The MET protein in the cases with MET amplification was 100% positive. PMID: 28756651
  35. Lower CA125 serum levels, negative vascular invasion, and wild-type BRAF status were significantly associated with improved 2-year DFS rates among patient with stage III disease who received adjuvant chemotherapy. PMID: 29562502
  36. genetic association/nutrigenomic studies in population in Seoul, Republic of Korea: Data suggest that (1) relatively low iodine intake and (2) more than excessive iodine intake are significant risk factors for occurrence of BRAF mutations in thyroid gland and may be risk factors for development of PTC (papillary thyroid cancer) in iodine-replete area. PMID: 28258306
  37. The BRAF gene has been reported to be mutated in some human cancers. The BRAF mutations have been implicated in ameloblastoma. PMID: 28650588
  38. The BRAFV600E mutation status may not impact the clinical response to radioiodine therapy for papillary thyroid carcinoma patients PMID: 29762246
  39. Children with Langerhans cell histiocytosis (LCH) tend to have a high overall survival rate and a high incidence rate of BRAF-V600E mutation. PMID: 29658453
  40. BRAF mutations more frequently affected individuals younger than 61 with phototype II. In contrast, NRAS mutations were more frequent in phototype III cases. Mutations of both genes were more frequent in cases with satellitosis in the first melanoma, and in cases with ulceration in the subsequent lesions. PMID: 29180316
  41. Identification of KRAS/NRAS/BRAF mutation status is crucial to predict the therapeutic effect and determine individual therapeutic strategies for patients with colorectal cancer. PMID: 29335867
  42. we did not observe GNAS or BRAF mutations in urachal adenocarcinomas PMID: 28285720
  43. Study finds infrequent BRAF alterations but enriched FGFR alterations in adults as compared with that reported in pediatric pilocytic astrocytomas. In addition, coexistent BRAF and FGFR alterations and a significant association of FGFR alterations with age and tumor location were noted. PMID: 27608415
  44. a low frequency of BRAF or KRAS mutation in Chinese patients with low-grade serous carcinoma of the ovary PMID: 29273082
  45. genetic association studies in population in China: Data suggest that, in patients with unilateral papillary thyroid carcinoma, a mutation in BRAF (V600E) plus multi-focality are both independently and synergically associated with CLNM (central lymph node metastasis) in the population studied. PMID: 29070763
  46. RHEB Y35N expressing cells undergo cancer transformation due to decreased interaction between RHEB and BRAF resulting in overactive RAF/MEK/ERK signaling. Taken together with the previously established function of RHEB to activate mTORC1 signaling, it appears that RHEB performs a dual function; one is to suppress the RAF/MEK/ERK signaling and the other is to activate mTORC1 signaling. PMID: 29320991
  47. The MLH1-93 AA genotype is significantly associated with promoter hypermethylation and MLH1 loss in the context of Sessile serrated adenoma of dysplasia. BRAF mutant microsatellite stable colorectal cancers with the AA genotype most likely arise in traditional serrated adenomas since the A allele does not predispose to methylation in this context. PMID: 29304767
  48. Knowing the mutation status of KRAS, BRAF or PIK3CA in stage II colorectal cancer can significantly improve the accuracy of prognoses. PMID: 28685592
  49. Mutated Liquid-based FNAs BRAF, N/HRAS and TERT mutations were significantly associated with malignancy regardless of the cytological classification PMID: 29094776
  50. our study suggests that an activating BRAF I463T mutation was associated with eosinophilic cystitis. Importantly, analysis of ctDNA obtained through "liquid biopsies" can identify potentially important genomic alterations in patients for whom biopsy may be difficult in terms of risk or cost. PMID: 28829677

Show More

Hide All

Involvement in disease
Colorectal cancer (CRC); Lung cancer (LNCR); Familial non-Hodgkin lymphoma (NHL); Cardiofaciocutaneous syndrome 1 (CFC1); Noonan syndrome 7 (NS7); LEOPARD syndrome 3 (LPRD3)
Subcellular Location
Nucleus. Cytoplasm. Cell membrane.
Protein Families
Protein kinase superfamily, TKL Ser/Thr protein kinase family, RAF subfamily
Tissue Specificity
Brain and testis.
Database Links

HGNC: 1097

OMIM: 114500

KEGG: hsa:673

STRING: 9606.ENSP00000288602

UniGene: Hs.324250

CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To